Research & Market Insights

ABK Biomedical Completes Enrollment in ROUTE90 Pivotal FDA IDE Study for Liver Cancer Treatment

Image

SHERIDAN, WYOMING - April 12, 2026 - ABK Biomedical has completed enrollment of all 120 patients in ROUTE90, its pivotal U.S. FDA Investigational Device Exemption study evaluating Eye90 microspheres® for unresectable hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The milestone positions the Halifax-based medical device company to finalize one-year patient follow-up, then submit a Premarket Approval (PMA) application to the FDA. Eye90 microspheres hold FDA Breakthrough Device Designation, signaling regulatory recognition of the device's potential to address an unmet clinical need in liver cancer care.

Septodont's Biodentine and BioRoot Flow Clinical Data Reshape Restorative and Endodontic Protocols in 2026

SHERIDAN, WYOMING - April 10, 2026 - Dental clinicians managing deep cavity restorations and endodontic retreatment decisions now have a richer evidence base to draw from, as Septodont USA's February 2026 clinical newsletter consolidates two-year trial outcomes for BioRoot® Flow and four documented case studies applying Biodentine® in the Bio-Bulk Fill technique for indirect restorations.

Biodentine Bio-Bulk Fill: four clinical cases document deep cavity restoration

Septodont's Case Studies Collection 28 presents workflows from four clinicians who used Biodentine®'s dentine-like mechanical and biological properties to restore deep cavities using the Bio-Bulk Fill technique. The cases extend the application of the material to symptomatic cracked teeth - a notoriously difficult clinical scenario where pulp status is uncertain and cavity geometry is irregular.

TÜV Association's 2026 Plant Safety Report Highlights Regulatory Pressure on Industrial Facility Operators

SHERIDAN, WYOMING - April 10, 2026 - Industrial facility operators across Germany and the broader DACH region face tightening inspection and compliance requirements in 2026, as the TÜV Association's annual Plant Safety Report (Anlagensicherheitsreport) documents the current state of accident prevention, technical inspections, and regulatory oversight for hazardous installations. The report forms a critical reference point for plant managers, insurers, and regulators assessing risk exposure across chemical, energy, and heavy manufacturing sectors.

ETSI Publishes 6G ISAC Security and Sustainability Framework in GR ISC 004

SHERIDAN, WYOMING - April 09, 2026 - Network architects and compliance teams designing next-generation infrastructure face a binding constraint: 6G Integrated Sensing and Communications (ISAC) systems introduce sensing capabilities that existing security and privacy frameworks do not cover, and ETSI's newly published GR ISC 004 defines the technical and non-technical requirements that vendors and operators must address before these systems can be responsibly deployed.

What ETSI GR ISC 004 covers

The European Telecommunications Standards Institute's Industry Specification Group on Integrated Sensing and Communications published ETSI GR ISC 004, a structured report cataloguing 19 key issues spanning security, privacy, trustworthiness, and sustainability in 6G ISAC environments. Of those 19 issues, 15 address security and privacy, while the remaining four focus on sustainability dimensions unique to systems that sense as well as communicate.

ETSI report maps security, privacy and sustainability requirements for 6G ISAC

Image
ETSI report maps security, privacy and sustainability requirements for 6G ISAC

SHERIDAN, WYOMING - March 31, 2026 - 6G planning in 2026 is shifting from pure performance targets to risk-managed design, as network, sensing and AI functions increasingly have to be evaluated together for security, privacy, trustworthiness and sustainability. ETSI has published ETSI GR ISC 004, a report from its Industry Specification Group on Integrated Sensing and Communications that examines how future 6G systems using ISAC will need safeguards for sensing data, human privacy, signal integrity and environmental performance.

IATA's 2025 safety data sharpens 2026 airline focus on runway infrastructure, turboprop risk and audit-backed oversight

Image

SHERIDAN, WYOMING - March 23, 2026 - Airline operators, airport managers and regulators enter 2026 with clearer pressure points for capital planning and compliance, as IATA's 2025 safety data shows better overall accident rates but higher fatalities, continued turboprop exposure and a measurable role for airport infrastructure in accident outcomes. The report covers 38.7 million flights in 2025, with 51 accidents and an all-accident rate of 1.32 per million flights, better than 1.42 in 2024 but slightly above the 2021-2025 average of 1.27. Fatal accidents rose to eight from seven in 2024, and onboard fatalities increased to 394 from 244, while fatality risk reached 0.17 per million flights versus 0.06 a year earlier.

Grinding operations push cooling lubricant data into core process control

Image

SHERIDAN, WYOMING - March 23, 2026 - Grinding manufacturers face a more data-driven operating model in 2026 as cooling lubricant management moves from a maintenance task into a direct lever for energy use, surface quality, uptime and scrap reduction. VDW highlights this shift through research and industrial practice around requirement-based coolant supply, where sensor data, standardized machine connectivity and cloud-based service platforms are used to stabilize grinding conditions and support more autonomous production.

Clinical scope

Image

SHERIDAN, WYOMING - March 23, 2026 - European hospitals evaluating 2026 imaging, intervention, and workforce plans now have a new validation pathway for AI-assisted neurovascular and oncology procedures as the SHERPA consortium starts seven clinical studies focused on workflow automation, precision support, and staff-pressure reduction in minimally invasive care. The four-year project has a total budget of EUR 21.5 million, is coordinated by Philips, and is co-funded by the EU Innovative Health Initiative and industry partners. Its work targets minimally invasive treatment workflows for brain aneurysms, liver tumors, and lung biopsy settings where specialized expertise is limited and procedure complexity is high.

Roche reports Phase II obesity data for petrelintide with 10.7% weight reduction at 42 weeks

Image

SHERIDAN, WYOMING - March 13, 2026 - Roche has reported positive Phase II results for petrelintide, an amylin analog being developed for people living with overweight and obesity. According to the company, petrelintide delivered up to 10.7% mean body weight reduction at week 42 compared with 1.7% for placebo, with a p-value of less than 0.001. Roche also said the maximally effective dose showed placebo-like tolerability, with no vomiting cases and no treatment discontinuations due to gastrointestinal adverse events. For the obesity treatment market, the update is relevant because efficacy and tolerability remain central to prescribing, adherence and competitive positioning.

IATA 2025 Safety Report: Fewer Accidents but Higher Onboard Fatalities Raise Operational Questions

Image

SHERIDAN, WYOMING - March 09, 2026 - The International Air Transport Association (IATA) released its 2025 Annual Safety Report, presenting a mixed safety picture for airlines and related operators: total accidents fell year-on-year, but fatal accidents and onboard fatalities rose. The report lists 51 accidents among 38.7 million flights in 2025, down from 54 accidents among 37.9 million flights in 2024, while fatal accidents increased to eight and onboard fatalities rose to 394. For executives and operational leaders, these outcomes highlight where safety performance has improved and where targeted intervention remains necessary to reduce catastrophic outcomes.